Xenon Pharmaceuticals Inc. Stock News

Brokerages expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xenon Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.67). Xenon Pharmaceuticals reported earnings of ($0.34) per []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235 P

Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups

Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups

BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on

BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021).

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be present

Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-s

Equities analysts forecast that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will post $7.10 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Xenon Pharmaceuticals earnings, with estimates ranging from $4.00 million to $8.80 million. Xenon Pharmaceuticals posted sales of $5.15 million in the same quarter last year, which would []

Analysts expect that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report earnings of ($0.42) per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Xenon Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.29). Xenon Pharmaceuticals posted earnings per share of []

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)s stock price dropped 6% during mid-day trading on Monday . The company traded as low as $27.11 and last traded at $27.26. Approximately 3,412 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 736,805 shares. The stock had previously closed at $28.99. XENE has []

Equities research analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce sales of $7.10 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Xenon Pharmaceuticals earnings. The lowest sales estimate is $4.00 million and the highest is $8.80 million. Xenon Pharmaceuticals posted sales of $5.15 million during the same quarter []